Last reviewed · How we verify
Ketorolac and Ropivacaine
At a glance
| Generic name | Ketorolac and Ropivacaine |
|---|---|
| Also known as | Toradol and Naropin |
| Sponsor | Maimonides Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Opioid-Free Pain Protocol After Shoulder Arthroplasty (PHASE4)
- Postoperative Pain Management Following Robotic Assisted Sacrocolpopexy (NA)
- Single Shot Exparel vs Catheters in Lower Extremity Trauma (PHASE4)
- Use of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery. (PHASE2, PHASE3)
- Pain Management Study (PHASE4)
- Prospective Opioid-Free AIS Fusion (PHASE4)
- Effect of RECK in Posterior Spinal Fusion (PHASE1, PHASE2)
- LIA vs. LIA + ACB-iPACK Block for Total Knee Arthroplasty (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketorolac and Ropivacaine CI brief — competitive landscape report
- Ketorolac and Ropivacaine updates RSS · CI watch RSS
- Maimonides Medical Center portfolio CI